Related News

Home » Business » Manufacturing

Glaxo's breast cancer drug gets second chance

BRITAIN'S cost-effectiveness watchdog is to reconsider a decision blocking the use of GlaxoSmithKline's breast cancer drug Tyverb on the National Health Service.

The National Institute for Health Clinical Excellence (NICE), which assesses drugs for reimbursement on the state health service, had ruled in March that the treatment had limited benefits and was too expensive.

But parts of a Glaxo appeal against the decision have been upheld in the light of new supplementary NICE advice for the assessment of treatments in small patient populations with a short life expectancy, the agency said yesterday.

The move means Glaxo will have a fresh opportunity to make a full submission to NICE under the new end of life criteria.


Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend